CVS Health Corporation $CVS Shares Sold by Kovitz Investment Group Partners LLC

Kovitz Investment Group Partners LLC lessened its holdings in shares of CVS Health Corporation (NYSE:CVS) by 81.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 48,191 shares of the pharmacy operator’s stock after selling 214,172 shares during the quarter. Kovitz Investment Group Partners LLC’s holdings in CVS Health were worth $3,824,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Caitong International Asset Management Co. Ltd raised its stake in CVS Health by 407.2% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after acquiring an additional 281 shares in the last quarter. Swiss RE Ltd. bought a new position in shares of CVS Health in the fourth quarter worth $26,000. Mcguire Capital Advisors Inc. bought a new position in shares of CVS Health in the fourth quarter worth $28,000. Ares Financial Consulting LLC acquired a new position in shares of CVS Health during the fourth quarter valued at $29,000. Finally, Dogwood Wealth Management LLC raised its stake in shares of CVS Health by 93.7% during the fourth quarter. Dogwood Wealth Management LLC now owns 370 shares of the pharmacy operator’s stock valued at $29,000 after purchasing an additional 179 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CVS has been the subject of several research analyst reports. Truist Financial upped their price objective on shares of CVS Health from $102.00 to $108.00 and gave the stock a “buy” rating in a report on Monday, June 1st. Royal Bank Of Canada boosted their price objective on CVS Health from $93.00 to $107.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. Leerink Partners reaffirmed an “outperform” rating and set a $98.00 target price on shares of CVS Health in a research note on Thursday, March 5th. Morgan Stanley lifted their target price on CVS Health from $106.00 to $111.00 and gave the stock an “overweight” rating in a report on Thursday, June 4th. Finally, UBS Group boosted their price target on shares of CVS Health from $100.00 to $115.00 and gave the stock a “buy” rating in a research report on Monday, June 8th. Twenty-two investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, CVS Health has a consensus rating of “Moderate Buy” and a consensus target price of $100.68.

Insider Buying and Selling

In other CVS Health news, Director Larry Robbins sold 1,983,538 shares of CVS Health stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the transaction, the director directly owned 6,213,261 shares in the company, valued at approximately $586,842,501.45. The trade was a 24.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Tilak Mandadi sold 69,551 shares of the business’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the sale, the executive vice president directly owned 10,133 shares in the company, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 3,441,551 shares of company stock valued at $323,703,977 in the last ninety days. Company insiders own 0.85% of the company’s stock.

CVS Health Trading Down 0.1%

Shares of CVS opened at $98.26 on Friday. The business’s 50-day moving average price is $89.31 and its 200 day moving average price is $81.48. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. The stock has a market capitalization of $125.38 billion, a P/E ratio of 43.29, a P/E/G ratio of 0.96 and a beta of 0.62. CVS Health Corporation has a 1-year low of $58.50 and a 1-year high of $102.77.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping the consensus estimate of $2.21 by $0.36. The company had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period last year, the company posted $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Analysts expect that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.